Justin Skoble is the Vice President of Technical Operations at Caribou Biosciences, Inc., where he is responsible for producing the Company’s GMP materials. Caribou is a leading company in CRISPR genome editing and is developing a pipeline of off-the-shelf CAR-T cell therapies, other gene-edited cell therapies, and engineered gut microbes. Before joining Caribou in 2019, Justin was most recently Chief Development Officer at Actym Therapeutics Inc. where he lead the development of microbial therapeutics for oncology. Prior to Actym, he served in various positions of increasing responsibility in immuno-oncology and vaccine development at Aduro Biotech, Anza Therapeutics, and Cerus Corporation. Justin has authored over 12 publications in peer-reviewed journals and is an inventor on numerous U.S. and foreign patents and patent applications. Justin earned his undergraduate degree in Biology from Vassar College and his Ph.D. in Molecular and Cell Biology from the University of California, Berkeley. He did his post-doctoral fellowship at the University of California, San Francisco.
